(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2011 (24.03.2011)

PCT

(10) International Publication Number
WO 2011/035335 A3

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 38/43* (2006.01)
A61K 9/10 (2006.01) *A61K 38/48* (2006.01)

(21) International Application Number:
PCT/US2010/049723

(22) International Filing Date:
21 September 2010 (21.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/244,353 21 September 2009 (21.09.2009) US

(71) Applicants *(for all designated States except US)*: **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, Illinois 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MATTHIESSEN, H., Peter** [DE/AT]; Vorgartenstr. 129-143/1/5, A-1020 Vienna (AT). **TURECEK, Peter, L.** [AT/AT]; Hauptstrasse 59g, A-3400 Klosterneuburg (AT). **SCHWARZ, Hans-Peter** [AT/AT]; Weimarer Strasse 76, A-1180 Vienna (AT).

(74) Agents: **PARENT, Annette, S.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, California 94111-3834 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
1 December 2011

(54) Title: STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS

(57) Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.

WO 2011/035335 A3